Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan

Psychiatry and Clinical Neurosciences

Volumn 66, Issue 4, 2012, Pages 313-321

  Ye, Wenyu ^a   Fujikoshi, Shinji ^a   Nakahara, Naohiro ^a   Takahashi, Michihiro ^a,b   Ascher Svanum, Haya ^a   Ohmori, Tetsuro ^c  

^a ELI LILLY AND COMPANY   (United States)

^b Terauchi Takahashi Psychiatric Clinic   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

olanzapine; risperidone; schizophrenia; treatment outcome

Indexed keywords

OLANZAPINE; RISPERIDONE;

ADULT; AKATHISIA; AMENORRHEA; ARTICLE; BODY WEIGHT; COGNITIVE DEFECT; DEPRESSION; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSTONIA; FEMALE; GALACTORRHEA; GYNECOMASTIA; HOSPITAL PATIENT; HUMAN; JAPAN; LIBIDO; MAJOR CLINICAL STUDY; MALE; MENSTRUATION DISORDER; MENTAL PATIENT; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTPATIENT; PARKINSONISM; PROSPECTIVE STUDY; QUALITY OF LIFE; REMISSION; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DRUG RESISTANCE; FEMALE; HUMANS; INCOME; JAPAN; MALE; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; RETREATMENT; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; WEIGHT GAIN;

EID: 84861552965     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2012.02351.x     Document Type: Article

References (31)

1. Buchanan RW, Kreyenbuhl J, Kelly DL, et al,. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr. Bull. 2010; 36: 71-93.
2. Canadian Psychiatric Association. Clinical practice guidelines. Treatment of schizophrenia. Can. J. Psychiatry. 2005; 50: 7S-57S.
3. Lehman AF, Lieberman JA, Dixon LB, et al,. Practice guideline for the treatment of patients with schizophrenia, second edition. Am. J. Psychiatry 2004; 161: 1-56.
4. Lieberman JA, Stroup TS, McEvoy JP, et al,. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005; 353: 1209-1223.
5. Park S, Ross-Degnan D, Adams AS, Sabin J, Kanavos P, Soumerai SB,. Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: Population-based study. Br. J. Psychiatry 2005; 187: 137-142.
6. Liu-Seifert H, Adams DH, Kinon BJ,. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med. 2005; 3: 21.
7. Leucht S, Kissling W, Davis JM,. Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol. Med. 2009; 39: 1591-1602.
8. Leucht S, Komossa K, Rummel-Kluge C, et al,. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am. J. Psychiatry 2009; 166: 152-163.
9. Suzuki T, Uchida H, Watanabe K, et al,. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone? A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting. Psychopharmacology (Berl.) 2007; 195: 285-295.
10. Stroup TS, Lieberman JA, McEvoy JP, et al,. Results of phase 3 of the CATIE schizophrenia trial. Schizophr. Res. 2009; 107: 1-12.
11. Shinfuku N, Tan CH,. Pharmacotherapy for schizophrenic inpatients in East Asia: changes and challenges. Int. Rev. Psychiatry 2008; 20: 460-468.
12. Yoshimura R, Okamoto T, Nakamura J, et al,. Prescription pattern of antipsychotic drugs for schizophrenic inpatients in Japan: research on East Asia Psychotropic Prescription Pattern-Antipsychotics study. Psychiatry Clin. Neurosci. 2006; 60: 778-779.
13. Chong M, Tan CH, Fujii S, et al,. Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change. Psychiatry Clin. Neurosci. 2004; 58: 61-67.
14. Oshima I, Mino Y, Inomata Y,. How many long-stay schizophrenia patients can be discharged in Japan? Psychiatry Clin. Neurosci. 2007; 61: 71-77.
15. Kuramochi M, Ono H, Nakahara N, et al,. Health outcome survey of olanzapine therapy in patients with schizophrenia: Analytical results of the post-marketing special survey of olanzapine. Jpn. J. Clin. Psychopharmacol. 2009; 12: 71-89 (in Japanese).
16. Haro JM, Kamath SA, Ochoa S, et al,. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr. Scand. Suppl. 2003; 416: 16-23.
17. Kay SR, Opler LA, Fiszbein A,. Positive and Negative Syndrome Scale (PANSS) User's Manual. Multi-Health Systems, Inc., North Tonawanda, NY, 2000.
18. The EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990; 16: 199-208.
19. Haro JM, Edgell ET, Novick D, et al,. Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr. Scand. 2005; 111: 220-231.
20. Haro JM, Novick D, Suarez D, et al,. Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. J. Clin. Psychopharmacol. 2006; 26: 571-578.
21. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157-163.
22. Stroup TS, McEvoy JP, Swartz MS, et al,. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr. Bull. 2003; 29: 15-31.
23. Nakanishi M, Setoya Y, Kodaka M, et al,. Symptom dimensions and needs of care among patients with schizophrenia in hospital and the community. Psychiatry Clin. Neurosci. 2007; 61: 495-501.
24. Soni SD, Mallik A, Reed P, Gaskell K,. Differences between chronic schizophrenic patients in the hospital and in the community. Hosp. Community Psychiatry 1992; 43: 1233-1238.
25. Carlson CD, Cavazzoni PA, Berg PH, Wei H, Beasley CM, Kane JM,. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. J. Clin. Psychiatry 2003; 64: 898-906.
26. Tran PV, Hamilton SH, Kuntz AJ, et al,. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J. Clin. Psychopharmacol. 1997; 17: 407-418.
27. Conley RR, Mahmoud R,. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am. J. Psychiatry 2001; 158: 765-774.
28. Ciudad A, Olivares JM, Bousoño M, Gõmez JC, Alvarez E,. Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial. Prog. Neuropsychopharmacol Biol. Psychiatry 2006; 30: 1515-1522.
29. Dossenbach M, Arango-Dávila C, Silva Ibarra H, et al,. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. J. Clin. Psychiatry 2005; 66: 1021-1030.
30. Takahashi H, Kamata M, Yoshida K, Ishigooka J, Higuchi H,. Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial. J. Clin. Psychiatry 2006; 67: 1577-1582.
31. Takahashi H, Yoshida K, Ishigooka J, Higuchi H,. Switching to risperidone after unsuccessful treatment of olanzapine in the first-episode schizophrenia: an open trial. Prog. Neuropsychopharmacol Biol. Psychiatry 2006; 30: 1067-1072.